Proof-of-Concept Study
An early-phase clinical trial (typically Phase IIa) designed to determine whether a drug produces the expected biological effect in patients. Proof-of-concept results provide the first human evidence that the drug's mechanism of action translates into clinical activity.
Technical Context
Phase IIa proof-of-concept studies typically enrol 20-100 patients and assess whether the drug produces detectable biological or clinical effects over 4-12 weeks. They may use biomarker endpoints (faster to measure than clinical outcomes) and enriched populations (selecting patients most likely to respond based on disease severity, genetic markers, or biomarker levels). For a new GLP-1 RA, PoC might demonstrate: HbA1c reduction ≥0.5% vs placebo at 12 weeks. For a research peptide transitioning from preclinical to clinical, PoC demonstrates that the mechanism of action identified in animal models translates to human biology. Failed PoC saves enormous development costs by identifying ineffective compounds before Phase III investment (~$100-300M for a typical Phase III programme).